Mitsuo sawai today received approvals by the ministry of health. The changes in bone mineral density bmd and bone turnover markers were investigated at 3 and 6 months, and adverse events, including the presence or absence of an incident osteoporotic fracture, were examined over a period of 6 months. It is approved for use in japan for the treatment of osteoporosis. With regard to inhibition of bone resorption, minodronic acid hydrate is times more effective than etidronate and 10100 times more effective than alendronic acid. Pharmacokinetics and tolerability of minodronic acid and. Affygility solutions has an occupational exposure limit oel and control band assignment for this active pharmaceutical ingredient api. With regard to inhibition of bone resorption, minodronic acid hydrate is times. The minodronic acid solution was brought to the final volume with water and filter sterilized through a 0. They are used for the treatment of osteoporosis and other bone disorders that cause bone fragility and diseases where bone resorption is excessive. One murine and eight human rcc cell lines were used for the in vitro studies and were subjected to a modified 34,5.
Discovery and development of bisphosphonates wikipedia. Abstract objectives minodronic acid hydrate, an oral bisphosphonate, has a greater inhibitory effect on bone resorption than do other approved. Minodronic acid bronjinduced fractured mandible, successfully treated with teriparatide. The present invention relates to an industrially advantageous, costeffective, and reproducible process for preparation of pure minodronic acid, including salts, hydrates and polymorphs thereof, by using ecofriendly process for preparation of key intermediate, in high yield and high purity. With regard to inhibition of bone resorption, minodronic acid hydrate is times more effective than etidronic acid and 10100 times more effective than alendronic acid. In part 3, a single oral dose of minodronic acid 1 mg was administered to elderly volunteers. The present invention particularly relates to a process for the preparation of minodronic acid. The effects of the ppi rabeprazole on bone metabolism were compared with those of minodronic acid, a bisphosphonate clinically administered.
Bonoteo, recalbon, minodronic acid hydrate ono5920. Here, we have investigated the therapeutic efficacy of ym529 against renal cell cancer rcc alone or in combination with ifn both in vitro and in vivo. Efficacy and safety of minodronic acid hydrate in patients with. References this pharmacologyrelated article is a stub. Due to its excellent preclinical activity profile, minodronic acid was selected for further development. Osteoporosis is common in postmenopausal women and patients in corticosteroid treatment where biphosphonates have been proven a valuable treatment and. It is then separated from the bone by acid released by osteoclasts during the bone resorption process and selectively taken up by osteoclasts. Minodronic acid is a thirdgeneration bisphosphonate drug. Minodronic acid is used to treat and prevent osteoporosis. Minodronic acid hydrate or control once a day for 48 weeks results. A thirdgeneration bisphosphonate, minodronic acid ym529, successfully prevented the growth of bladder cancer in vitro and in vivo. A form of minodronic acid 50 mg requiring oncemonthly administration has been developed and is currently being used clinically.
Recently, exploiting the crosscoupling tendency of cuo nps, reddy et al. It is used for osteoporosis and vitamin d3 deficiency. A thirdgeneration bisphosphonate, minodronic acid ym529. Structure, properties, spectra, suppliers and links for. In part 1, minodronic acid tablets were administered to young volunteers at doses of 1, 2, and 4 mg. Adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme nacetylglutamate synthase. Pharmacokinetics and tolerability of minodronic acid. Minodronic acid improves the patients condition by performing the following functions. Minodronic acid hydrate was approved by pharmaceuticals and medicals devices agency of japan pmda on jan 21, 2009. Minodronate is a thirdgeneration bisphosphonate that was developed and approved for clinical use in osteoporosis. The safety was found to be comparable to that of the comparator drug.
Noninferiority of the efficacy of minodronic acid hydrate to that of the comparator drug was verified. A link to download a pdf version of the drug profile will be included in your email receipt. Wo20140986a2 an improved process for preparation of. The present invention relates to an improved process for the preparation of minodronic acid.
A comparative study between this new formulation and oncedaily minodronic acid 1 mg showed no significant differences between the two formulations in terms of improvement rates in lumbarspine and hipjoint bone. Effects of minodronic acid and alendronate on bone. Effects of rabeprazole on bone metabolic disorders in a. Buy minodronic acid monohydrate cas 155648605, a biochemical for proteomics research, from santa cruz. Increasing absorption of calcium and phosphorus required for strong bones. A thirdgeneration bisphosphonate, minodronic acid ym529 nature. Over 10 million scientific documents at your fingertips. Eight molecules in 19 presentations of generic drugs. Bisphosphonates are an important class of drugs originally introduced about half a century ago. This page was last edited on 27 september 2017, at 18. A oncedaily formulation of the bisphosphonate is already marketed in japan. Study on bone fracture doubleblind comparative study. In the 4mg dose group, minodronic acid cmax and auc01 were reduced by 55% and 72%, respectively, with a highfat breakfast compared with fasted conditions.
Full text minodronate for the treatment of osteoporosis. The agent also showed activity against tumorinduced osteolysis in rats and mice and antimyeloma effects in vitro. Suppressing the suppressing the osteoclastic function. Various copper salts have been used as lewis acid in homogeneous catalysis.
Minodronic acid ym529 is a thirdgeneration nitrogencontaining bisphosphonate. Nitrogencontaining bisphosphonates, such as minodronic acid, induce osteoclast apoptosis by inhibiting farnesyl pyrophosphate. A list of us medications equivalent to minodronic acid hydrate is available on the drugs. The aim of this study was to evaluate the pharmacokinetic profiles and tolerability of minodronic acid in healthy subjects, as well as to assess the effects of food and age on the pharmacokinetics.
Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in japan. Minodronic acid ym529 is a thirdgeneration bisphosphonate bp that has been shown to directly and indirectly prevent proliferation, induce apoptosis, and inhibit metastasis of various types of. Tetrahedron vol 75, issue 8, pages 9291114 22 february 2019. After a single dose of minodronic acid 1 mg, plasma cmax and auc01 were both 1. Alendronic acidminodronic acidzoledronic acid springerlink. Efficacy and safety of oral bisphosphonate minodronic acid in stable maintenance dialysis. Bisphosphonates reduce bone calcification and bone resorption. Effect of minodronic acid hydrate on hip geometry in.
Minodronic acid is a thirdgeneration bisphosphonate being developed for the treatment of osteoporosis. Abstract objective to study the effect of minodronic acid ono. Significant early responses at 36 months after the start of administration were observed in all three regions of the proximal femur narrow neck, intertrochanter, and shaft in. Minodronic acid hydrate is a medicine available in a number of countries worldwide. Minodronic acid recalbon, bonoteo, a thirdgeneration bisphosphonate, was approved in japan for the oral treatment of osteoporosis.
Efficacy and safety of minodronic acid hydrate in patients. Minodronic acid increases the bone mineral density and strength by inhibiting osteoclastic bone resorption. In part 2, after a single dose, young volunteers in the 1mg dose group received repeated oral doses of minodronic acid once daily for 7 days. Induction of creatine kinase release from cultured. Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity. Addition of aluminum ions to minodronic acid solution. All structured data from the file and property namespaces is available under the creative commons cc0 license. Minodronic acid is a thirdgeneration bisphosphonate approved in japan for the oral treatment of osteoporosis. Minodronic acid hydrate regulatory update in july, japans ministry of health, labor and welfare mhlw approved an nda for monthly bonoteo recalbon minodronic acid to treat osteoporosis. Failure of stability prediction for minodronic acid. Minodronic acid oel fastrac with ade affygility solutions. Minodronic acid significantly decreased the serum calcium level compared with the level in the tg control group p minodronic acid or rabeprazole. Fp473efficacy and safety of oral bisphosphonate minodronic acid. Wo2016024287a1 an improved process for preparing pure.
Cas registry number chemical abstracts service 0127657425. Read effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys, bone on deepdyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Minodronic acid monohydrate ono5920dc chemicals issuu. Minodronic acid ym529 is a thirdgeneration nitrogencontaining. Cuo nanoparticles nps were used for cn, cs, co crosscoupling reactions and carylation. Osaka, japan february 15, 2018 sawai pharmaceutical co. Recently, minodronic acid was shown to have bone resorptive activity in a number of preclinical models. Ono pharmaceutical and astellas pharma are developing minodronic acid, a bisphosphonate compound for the treament of osteoporosis.
868 207 672 520 324 792 209 1300 433 227 1558 396 1122 772 249 1042 570 1096 410 1418 1396 709 1098 1273 1130 73 854 557 1256 525 341 1285 1282 93 376 1152 870